Twist Bioscience Corp 8-K

What Happened
Twist Bioscience Corporation announced on January 12, 2026 that it issued a press release with preliminary, unaudited revenue results for the first quarter ended December 31, 2025. The press release is furnished as Exhibit 99.1 to the Form 8-K. The company cautioned that these revenue expectations are preliminary and may change after completion of internal control, review and audit procedures.

Key Details

• Event filed on Form 8-K under Item 2.02 (Results of Operations and Financial Condition) on January 12, 2026.
• Quarter covered: fiscal Q1 ended December 31, 2025.
• Reported figures are preliminary and unaudited; the company states they may differ materially from final amounts.
• Press release announcing the preliminary results is included as Exhibit 99.1 to the 8-K.

Why It Matters
Preliminary revenue announcements give an early look at quarterly results but carry added uncertainty because they haven’t been finalized or audited. Investors should treat these numbers as tentative and wait for the company’s subsequent filings (unaudited financial statements and any related earnings release or conference call) for confirmed earnings and revenue details. Keywords to note for follow-up: earnings, revenue, quarterly results.